Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s Actemra Receives Breakthrough For Systemic Sclerosis; Potential Future Beneficiary of OPEN ACT?

This article was originally published in RPM Report

Executive Summary

The potential new indication for Actemra could be an early beneficiary of a six-month patent extension, if the Cures legislation is enacted and orphan designation exclusivity remains a feature of the bill.

You may also be interested in...



Rare Disease OPEN-ing In PDUFA Possible For Drug Repurposing Advocates

OPEN ACT would provide additional six months of exclusivity when existing drugs are approved for rare diseases; congressional debate over the measure could get bogged down in drug pricing issues.

Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'

US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.

SMA Patient Meeting Showcases FDA Flexibility – And Appreciation From Advocates

US agency's top neurology review officials received warm reception during Patient Focused Drug Development meeting for Spinal Muscular Atrophy. They also delivered a strong message of continued engagement beyond the first drug approval.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel